Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Personalized Management in Psoriasis and Atopic Dermatitis
share announcement

Personalized Management in Psoriasis and Atopic Dermatitis

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 20 March 2025 | Viewed by 4870

Special Issue Editors

Dr. Mario Valenti

E-Mail Website
Guest Editor
1. Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
2. Department of Biomedical Sciences, Humanitas University, Milan, Italy
Interests: psoriasis; atopic dermatitis; hidradenitis suppurativa; melanoma; non-melanoma skin cancers; confocal microscopy
Prof. Dr. Antonio Costanzo

E-Mail Website
Guest Editor
1. Dermatology Unit, Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy
2. Humanitas Clinical and Research Center, Scientific Institute for Research, Hospitalization and Healthcare, 20089 Rozzano, Italy
Interests: skin; psoriasis; atopic dermatitis

Special Issue Information

Dear Colleagues,

The development of a multitude of biological drugs and small molecules (e.g., JAK inhibitors) has led to a paradigm shift in the treatment of inflammatory skin diseases. These drugs are changing the lives of millions of dermatological patients around the world, and they are also helping clinicians to better understand the pathophysiology of several immune-mediated cutaneous diseases, including psoriasis, atopic dermatitis, chronic urticaria, and hidradenitis suppurativa; however, data are still limited on the place in therapy of different drugs in each subpopulation of patients, according to comorbidities, disease severity, and previous exposure to other systemic drugs. Furthermore, the search for biomarkers that might help with classification and therapy selection is still ongoing. In this Special Issue, we will focus on new drugs for the treatment of psoriasis and atopic dermatitis, with a particular interest in real-world experiences, with the aim to explore possible tailor-made treatments for each patient. Both original research manuscripts and reviews, as well as short communications, are welcome to be submitted, to offer readers innovative perspectives on a patient-targeted approach for managing psoriasis and atopic dermatitis.

Dr. Mario Valenti
Prof. Dr. Antonio Costanzo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory skin diseases
  • immune-mediated diseases
  • psoriasis
  • psoriatic arthritis
  • atopic dermatitis
  • biologics
  • JAK inhibitors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1298 KiB  
Article
Epidermal Barrier Parameters in Psoriasis: Implications in Assessing Disease Severity
by Silviu-Horia Morariu, Ovidiu Simion Cotoi, Oana Mirela Tiucă, Maria Crișan, Liuba Garaga, Robert Aurelian Tiucă, Claudia Raluca Mariean, Florin Corneliu Buicu and Alin Codrut Nicolescu
J. Pers. Med. 2024, 14(7), 728; https://doi.org/10.3390/jpm14070728 - 5 Jul 2024
Viewed by 949
Abstract
Psoriasis is characterized by an aberrant immune response due to myeloid dendritic cells and T helper cells intertwining with keratinocyte hyperproliferation. Skin integrity alterations may predispose patients to physiological imbalances, such as xerosis, reduced elasticity, and increased friability. This study aims to assess [...] Read more.
Psoriasis is characterized by an aberrant immune response due to myeloid dendritic cells and T helper cells intertwining with keratinocyte hyperproliferation. Skin integrity alterations may predispose patients to physiological imbalances, such as xerosis, reduced elasticity, and increased friability. This study aims to assess the epidermal barrier dysfunction in chronic plaque psoriasis and gain a comprehensive view of the dynamic changes in the epidermal barrier during various topical therapies. Adult patients with chronic plaque psoriasis were enrolled in this observational study. For each patient, skin barrier parameters, stratum corneum hydration (SCH), transepidermal water loss (TEWL), elasticity, erythema, and melanin levels were measured in lesional and non-lesional skin. Two extensions of the initial study design, with subsequent epidermal barrier determinations, were made as follows: one in which patients with moderate psoriasis were treated with clobetasol propionate 0.5% and the second one in which mild psoriasis was treated with either clobetasol propionate 0.5% or clobetasol propionate 0.5% with 10% urea. TEWL and erythema were found to be higher in the sites affected by psoriatic lesions than the unaffected sites, while SCH and elasticity were decreased. Severe psoriasis presented with higher TEWL (p = 0.032), erythema (p = 0.002), and lower SCH (p < 0.001) compared with the mild and moderate forms. SCH significantly improved during clobetasol propionate 0.5% treatment (p = 0.015). Clobetasol propionate 0.5% with 10% urea was found to be superior to clobetasol propionate 0.5% in improving TEWL and SCH in psoriasis. Full article
(This article belongs to the Special Issue Personalized Management in Psoriasis and Atopic Dermatitis)
►▼ Show Figures

Figure 1

14 pages, 1852 KiB  
Article
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience
by Luca Mastorino, Paolo Dapavo, Caterina Cariti, Sara Susca, Niccolò Siliquini, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Isotta Giunipero di Corteranzo, Francesco Leo, Pietro Quaglino and Simone Ribero
J. Pers. Med. 2024, 14(7), 718; https://doi.org/10.3390/jpm14070718 - 3 Jul 2024
Viewed by 1413
Abstract
Introduction: the selective IL-17 inhibitor secukinumab has demonstrated efficacy and safety in the treatment of moderate–severe psoriasis in recent years. Objective: evaluate effectiveness and drug survival (DS) of secukinumab in patients with psoriasis for up to 5 years. Methods: This is a retrospective [...] Read more.
Introduction: the selective IL-17 inhibitor secukinumab has demonstrated efficacy and safety in the treatment of moderate–severe psoriasis in recent years. Objective: evaluate effectiveness and drug survival (DS) of secukinumab in patients with psoriasis for up to 5 years. Methods: This is a retrospective study on a monocentric cohort of patients with psoriasis on secukinumab evaluating the achievement of PASI100, PASI90, and PASI ≤ 3 and DS analysis up to 260 weeks. DS multivariate analysis was carried out considering sex, age, age of onset of the disease, obesity, cardiovascular comorbidities, diabetes, involvement of difficult-to-treat sites, psoriatic arthritis, treatment-naïve status, and mean baseline PASI. Results: At baseline, we evaluated 255 patients on secukinumab. PASI100 was reached by 41.7% and 70.6% of patients at weeks 16 and 260, respectively. PASI90 showed a similar trend with 46.5% of patients achieving it at week 16 and 88.2% at week 260. Non-obese patients showed a faster response than patients with obesity in achieving PASI100, PASI90, and PASI ≤ 3, with significant differences at 28 weeks [55% vs. 40% (p = 0.033), 64% vs. 49% (p = 0.038), and 76% vs. 62% (p = 0.036), respectively]. The estimated DS for secukinumab was 84.3% at 12 and 48% at 60 months. Obesity and smoking habits were associated with a higher risk of discontinuation in multivariate models (HR 1.6 CI 1.05–2.45, p = 0.028; HR 1.48 CI 1.01–2.17, p = 0.043, respectively). Conclusions: Secukinumab showed effectiveness for up to 5 years of treatment, with a high DS and achievement of PASI100, PASI90, and PASI < 3 at these time points. Only obesity reduced the response and maintenance of DS. Full article
(This article belongs to the Special Issue Personalized Management in Psoriasis and Atopic Dermatitis)
►▼ Show Figures

Figure 1

10 pages, 553 KiB  
Article
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study
by Giovanni Fiorillo, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo and Mario Valenti
J. Pers. Med. 2024, 14(2), 186; https://doi.org/10.3390/jpm14020186 - 7 Feb 2024
Cited by 3 | Viewed by 1761
Abstract
Psoriasis can have a significant impact on quality of life and productivity, especially with increased severity. However, there is limited evidence on biologics’ efficacy in highly severe cases compared to moderate-to-severe ones. This study aimed to evaluate the effectiveness and safety of novel [...] Read more.
Psoriasis can have a significant impact on quality of life and productivity, especially with increased severity. However, there is limited evidence on biologics’ efficacy in highly severe cases compared to moderate-to-severe ones. This study aimed to evaluate the effectiveness and safety of novel biological therapies in very severe psoriasis. We conducted a retrospective analysis on patients ≥ 18 years old affected by very severe psoriasis who had received a biological agent for at least 16 weeks. We used PASI to assess disease severity and effectiveness at weeks 16, 52, 104, and 156. Safety was evaluated by tracking treatment discontinuation rates and adverse events. This study included 29 males and 11 females, with a mean age of 55.80 years (SD 13.82). Cardiometabolic diseases were the most common comorbidities (25.00%). Twenty-eight (70.00%) patients had psoriasis involvement in at least one difficult-to-treat area. All patients completed 16 weeks of treatment. The mean PASI was 31.60 (SD 2.57) at baseline, 3.48 (SD 4.13) at week 16, 0.58 (SD 1.70) at week 52, 0.77 (SD 1.66) at week 104, and 1.29 (SD 2.12) at week 156. PASI90 and 100 were achieved by 52.50% and 30.00% of patients at week 16, by 96.15% and 80.77% at week 52, by 93.33% and 66.67% at week 104, and by 85.71% and 42.86% at week 156. PASIs ≤ 2 were achieved by 50.00% of patients at week 16, 88.46% at week 52, 86.67% at week 104, and 85.71% at week 156. Only two patients discontinued biologics due to complete remission, and mild AEs were reported by four patients. Our findings show that biologics are effective and well tolerated for treating very severe psoriasis, maintaining long-term effectiveness. Full article
(This article belongs to the Special Issue Personalized Management in Psoriasis and Atopic Dermatitis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop